Natixis Advisors, L.P. Regeneron Pharmaceuticals, Inc. Transaction History
Natixis Advisors, L.P.
- $63 Billion
- Q2 2025
A detailed history of Natixis Advisors, L.P. transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Natixis Advisors, L.P. holds 113,025 shares of REGN stock, worth $67.8 Million. This represents 0.09% of its overall portfolio holdings.
Number of Shares
113,025
Previous 116,232
2.76%
Holding current value
$67.8 Million
Previous $73.7 Million
19.51%
% of portfolio
0.09%
Previous 0.14%
Shares
32 transactions
Others Institutions Holding REGN
# of Institutions
1,418Shares Held
88.7MCall Options Held
1.98MPut Options Held
1.75M-
Vanguard Group Inc Valley Forge, PA9.42MShares$5.65 Billion0.08% of portfolio
-
Black Rock Inc. New York, NY8.45MShares$5.07 Billion0.2% of portfolio
-
Jpmorgan Chase & CO New York, NY5.66MShares$3.39 Billion0.28% of portfolio
-
State Street Corp Boston, MA4.83MShares$2.9 Billion0.1% of portfolio
-
Dodge & Cox San Francisco, CA3.83MShares$2.3 Billion1.21% of portfolio
About REGENERON PHARMACEUTICALS, INC.
- Ticker REGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 107,190,000
- Market Cap $64.3B
- Description
- Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...